Maple Capital Management Inc. grew its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 1.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 97,616 shares of the company’s stock after purchasing an additional 1,450 shares during the quarter. Eli Lilly and comprises about 2.1% of Maple Capital Management Inc.’s investment portfolio, making the stock its 18th biggest position. Maple Capital Management Inc.’s holdings in Eli Lilly and were worth $8,245,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in Eli Lilly and by 7,093.5% in the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after acquiring an additional 9,223,251 shares during the period. Renaissance Technologies LLC raised its holdings in Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after acquiring an additional 2,714,505 shares during the period. Bank of Montreal Can raised its holdings in Eli Lilly and by 85.4% in the 4th quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock worth $391,156,000 after acquiring an additional 2,133,606 shares during the period. Investec Asset Management LTD bought a new position in Eli Lilly and in the 4th quarter worth $163,570,000. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Eli Lilly and by 1,327.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,212,824 shares of the company’s stock worth $99,815,000 after acquiring an additional 1,127,856 shares during the period. Institutional investors and hedge funds own 77.58% of the company’s stock.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $76.50, for a total value of $65,790.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the transaction, the senior vice president now owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,261 shares of company stock worth $987,485. Company insiders own 0.20% of the company’s stock.
Several research analysts recently commented on the stock. TheStreet downgraded shares of Eli Lilly and from a “b” rating to a “c” rating in a report on Monday, March 5th. Bank of America decreased their price target on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 1st. JPMorgan Chase & Co. set a $105.00 price target on shares of Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Jefferies Group set a $93.00 price target on shares of Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Finally, Credit Suisse Group restated a “hold” rating and issued a $80.00 price target on shares of Eli Lilly and in a research report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and an average target price of $93.47.
Shares of Eli Lilly and Co (NYSE:LLY) opened at $78.75 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. Eli Lilly and Co has a 12-month low of $73.69 and a 12-month high of $89.09. The firm has a market cap of $85,993.48, a PE ratio of -393.73, a PEG ratio of 1.46 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.95 earnings per share. analysts anticipate that Eli Lilly and Co will post 4.87 earnings per share for the current year.
WARNING: This news story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/16/maple-capital-management-inc-acquires-1450-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.